Literature DB >> 22124531

Comparative analysis of different laparoscopic hysterectomy procedures.

Deslyn T G Hobson1, Anthony N Imudia, Zain A Al-Safi, George Shade, Michael Kruger, Michael P Diamond, Awoniyi O Awonuga.   

Abstract

PURPOSE: To compare the antecedent gynecological characteristics, indications for, and complications associated with, the different laparoscopic approaches to hysterectomy, in women with benign gynecological conditions.
METHODS: A retrospective cohort study of 957 patients who underwent laparoscopic supracervical (LSH), total (TLH), and assisted vaginal (LAVH) hysterectomies between January 2003 and December 2009.
RESULTS: Among 957 LH, 799 (83.5%) were LSH, 62 (6.4%) TLH, and 96 (10.1%) LAVH. Demographic characteristics were not different among the groups. Antecedent gynecologic conditions that were associated with the type of laparoscopic hysterectomy (LH) performed were: postmenopausal bleeding [LAVH vs. LSH, odds ratio (OR) 2.20; 95% confidence interval (CI) 1.04-4.65], previous pelvic surgery (TLH vs. LSH, OR 1.92; CI 1.05-3.52), previous cesarean delivery (LAVH vs. LSH, OR 0.39; CI 0.21-0.76), and prior hysteroscopy (LAVH vs. LSH, OR 0.29; CI 0.16-0.50). Preoperative diagnoses that were associated with the choice of LH were: menometrorrhagia (LAVH vs. LSH, OR 0.23; CI 0.14-0.38; TLH vs. LSH, OR 0.50; CI 0.26-0.98), uterine fibroids (LAVH vs. LSH, OR 0.25; CI 0.15-0.41), endometrial hyperplasia (TLH vs. LSH, OR 5.5; CI 2.04-14.84), and cervical dysplasia (TLH vs. LSH, OR 17.1; CI 6.83-42.79; LAVH vs. LSH, OR 8.05; CI 3.05-22.06). Estimated blood loss, operating time, and length of hospital stay were significantly reduced with LSH.
CONCLUSION: Antecedent gynecological history and the indications for surgery were associated with the type of LH performed in our institution. LSH was the most common approach and was associated with significantly less morbidity.

Entities:  

Mesh:

Year:  2011        PMID: 22124531     DOI: 10.1007/s00404-011-2140-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  A prospective, randomized clinical comparison between UltraCision and the novel sealing and cutting device BiCision in patients with laparoscopic supracervical hysterectomy.

Authors:  Ralf Rothmund; Mara Szyrach; Ali Reda; Markus D Enderle; Alexander Neugebauer; Florin-Andrei Taran; Sara Brucker; Andrea Hausch; Christian Wallwiener; Bernhard Kraemer
Journal:  Surg Endosc       Date:  2013-05-14       Impact factor: 4.584

2.  Hysterectomy via transvaginal natural orifice transluminal endoscopic surgery for nonprolapsed uteri.

Authors:  Chin-Jung Wang; Hui-Yu Huang; Chen-Ying Huang; Hsuan Su
Journal:  Surg Endosc       Date:  2014-10-01       Impact factor: 4.584

3.  The influence of persistent bleeding after supracervical hysterectomy on depressive and anxious symptoms: a prospective bicenter study.

Authors:  Carolin Spüntrup; M Banerjee; J Piana; M Hellmich; J Bojahr; B Bojahr; C Albus; G Noé
Journal:  Arch Gynecol Obstet       Date:  2022-03-01       Impact factor: 2.493

4.  Laparoscopic Hysterectomies: Our 10 Years Experience in a Single Laparoscopic Center.

Authors:  Ramesh Bettaiah; Chandana Anantha Rama Reddy
Journal:  J Obstet Gynaecol India       Date:  2015-02-17

5.  Robotic Trachelectomy After Supracervical Hysterectomy for Benign Gynecologic Disease.

Authors:  Ziv Tsafrir; Joelle Aoun; Rabbie Hanna; Eleni Papalekas; Lauren Schiff; Evan Theoharis; David Eisenstein
Journal:  JSLS       Date:  2016 Jul-Sep       Impact factor: 2.172

6.  Robotic single-site supracervical hysterectomy with manual morcellation: Preliminary experience.

Authors:  Dah-Ching Ding; Mun-Kun Hong; Tang-Yuan Chu; Yu-Hsun Chang; Hwan-Wun Liu
Journal:  World J Clin Cases       Date:  2017-05-16       Impact factor: 1.337

7.  A new technique for supracervical hysterectomy: Anterograde vaginal subtotal hysterectomy.

Authors:  Zi-Jun Li; Zhen-Xiang Jia; Ya-Qin Zheng
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.